What is RenBio?
Established in 2016 and headquartered in New York City, RenBio is dedicated to creating best-in-class antiviral antibody therapeutics. The company is also pioneering a next-generation antibody delivery platform, aiming to enhance the efficacy and accessibility of its treatments. RenBio operates within the competitive biotechnology sector, focusing on unmet needs in infectious disease treatment and prevention.
How much funding has RenBio raised?
RenBio has raised a total of $24.4M across 3 funding rounds:
Debt
$150K
Debt
$264K
Series A
$24M
Debt (2020): $150K with participation from PPP
Debt (2021): $264K led by PPP
Series A (2021): $24M supported by Ruentex Group
Key Investors in RenBio
Ruentex Group
Ruentex Group is a significant backer, likely providing strategic capital to companies with strong growth potential in the biotechnology sector.
PPP
Public-Private Partnership
Undisclosed investor
An undisclosed investor participated in the recent funding round, contributing to RenBio's strategic capital base.
What's next for RenBio?
The recent major strategic investment signals a strong vote of confidence in RenBio's technology and development trajectory. This capital infusion is expected to accelerate the company's preclinical research and development efforts, potentially moving its novel antibody therapeutics closer to clinical trials. The strategic nature of the funding suggests a focus on expanding market reach and solidifying partnerships within the pharmaceutical and biotechnology industries, positioning RenBio for future growth and potential commercialization.
See full RenBio company page
